Resveratrol Inhibits CD4+ T Cell Activation by Enhancing the Expression and Activity of Sirt1

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Zou, Ting ^a   Yang, Yi ^a   Xia, Fei ^a   Huang, Anfei ^a   Gao, Xiaoming ^a   Fang, Deyu ^b   Xiong, Sidong ^a   Zhang, Jinping ^a  

^a SOOCHOW UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PROTEIN C JUN; RESVERATROL; SIRTUIN 1;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; T LYMPHOCYTE ACTIVATION;

ACETYLATION; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL NUCLEUS; CELL PROLIFERATION; COLLAGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; IMMUNOPRECIPITATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; SIRTUIN 1; STILBENES;

EID: 84884489459     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075139     Document Type: Article

References (43)

1. Pervaiz S, (2003) Resveratrol: from grapevines to mammalian biology. FASEB J 17: 1975-1985. doi:10.1096/fj.03-0168rev. PubMed: 14597667.
2. Renaud S, de Lorgeril M, (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526. doi:10.1016/0140-6736(92)91277-F. PubMed: 1351198.
3. Kopp P, (1998) Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol 138: 619-620. doi:10.1530/eje.0.1380619. PubMed: 9678525.
4. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220. doi:10.1126/science.275.5297.218. PubMed: 8985016.
5. Bradamante S, Barenghi L, Villa A, (2004) Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 22: 169-188. PubMed: 15492766.
6. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, et al. (2002) Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 958: 439-447. doi:10.1016/S0006-8993(02)03543-6. PubMed: 12470882.
7. Sinha K, Chaudhary G, Gupta YK, (2002) Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci 71: 655-665. doi:10.1016/S0024-3205(02)01691-0. PubMed: 12072154.
8. Inoue H, Jiang XF, Katayama T, Osada S, Umesono K, et al. (2003) Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor α in mice. Neurosci Lett 352: 203-206. doi:10.1016/j.neulet.2003.09.001. PubMed: 14625020.
9. Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC, (2001) Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol 62: 1299-1308. doi:10.1016/S0006-2952(01)00775-4. PubMed: 11705464.
10. Sharma S, Chopra K, Kulkarni SK, Agrewala JN, (2007) Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin Exp Immunol 147: 155-163. PubMed: 17177975.
11. Wu SL, Yu L, Jiao XY, Meng KW, Pan CE, (2006) The Suppressive Effect of Resveratrol on Protein Kinase Cθ in Peripheral Blood T Lymphocytes in a Rat Liver Transplantation Model. Transplant Proc 38: 3052-3054. doi:10.1016/j.transproceed.2006.08.150. PubMed: 17112897.
12. Xuzhu G, Komai-Koma M, Leung BP, Howe HS, McSharry C, et al. (2012) Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis 71(1):: 129-135. doi:10.1136/ard.2011.149831. PubMed: 21953348.
13. Yang Y, Paik JH, Cho D, Cho JA, Kim CW, (2008) Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells. Int Immunopharmacol 8: 542-547. doi:10.1016/j.intimp.2007.12.006. PubMed: 18328445.
14. Park SJ, Ahmad F, Philp A, Baar K, Williams T, et al. (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421-433. doi:10.1016/j.cell.2012.01.017. PubMed: 22304913.
15. Tennen RI, Michishita-Kioi E, Chua KF, (2012) Finding a target for resveratrol. Cell 148: 387-389. doi:10.1016/j.cell.2012.01.032. PubMed: 22304906.
16. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196. doi:10.1038/nature01960. PubMed: 12939617.
17. Kaeberlein M, McVey M, Guarente L, (1999) The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 13: 2570-2580. doi:10.1101/gad.13.19.2570. PubMed: 10521401.
18. Zhang J, Lee SM, Shannon S, Gao B, Chen W, et al. (2009) The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 119: 3048-3058. doi:10.1172/JCI38902. PubMed: 19729833.
19. Williams RO, (2007) Collagen-induced arthritis in mice. Methods Mol Med 136: 191-199. doi:10.1007/978-1-59745-402-5_14. PubMed: 17983149.
20. Yamakuchi M, Ferlito M, Lowenstein CJ, (2008) miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 105: 13421-13426. doi:10.1073/pnas.0801613105. PubMed: 18755897.
21. Siemann EH, Creasy LL, (1992) Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 43: 49-52.
22. Nakata R, Takahashi S, Inoue H, (2012) Recent advances in the study on resveratrol. Biol Pharm Bull 35: 273-279. doi:10.1248/bpb.35.273. PubMed: 22382311.
23. de la Lastra CA, Villegas I, (2005) Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res 49: 405-430. doi:10.1002/mnfr.200500022. PubMed: 15832402.
24. Baur JA, Sinclair DA, (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506. doi:10.1038/nrd2060. PubMed: 16732220.
25. Qiang L, Lin HV, Kim-Muller JY, Welch CL, Gu W, et al. (2011) Proatherogenic abnormalities of lipid metabolism in SirT1 transgenic mice are mediated through Creb deacetylation. Cell Metab 14: 758-767. doi:10.1016/j.cmet.2011.10.007. PubMed: 22078933.
26. Ramadori G, Fujikawa T, Anderson J, Berglund ED, Frazao R, et al. (2011) SIRT1 deacetylase in SF1 neurons protects against metabolic imbalance. Cell Metab 14: 301-312. doi:10.1016/j.cmet.2011.06.014. PubMed: 21907137.
27. Chalkiadaki A, Guarente L, (2012) Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat Rev Endocrinol 8: 287-296. doi:10.1038/nrendo.2011.225. PubMed: 22249520.
28. Qiang L, Wang L, Kon N, Zhao W, Lee S, et al. (2012) Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell 150: 620-632. doi:10.1016/j.cell.2012.06.027. PubMed: 22863012.
29. Lee CW, Wong LL, Tse EY, Liu HF, Leong VY, et al. (2012) AMPK Promotes p53 Acetylation via Phosphorylation and Inactivation of SIRT1 in Liver Cancer Cells. Cancer Res 72: 4394-4404. doi:10.1158/0008-5472.CAN-12-0429. PubMed: 22728651.
30. Li L, Wang L, Li L, Wang Z, Ho Y, et al. (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21: 266-281. doi:10.1016/j.ccr.2011.12.020. PubMed: 22340598.
31. Lin Z, Yang H, Kong Q, Li J, Lee SM, et al. (2012) USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell 46: 484-494. doi:10.1016/j.molcel.2012.03.024. PubMed: 22542455.
32. Yao H, Chung S, Hwang JW, Rajendrasozhan S, Sundar IK, et al. (2012) SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest 122: 2032-2045. doi:10.1172/JCI60132. PubMed: 22546858.
33. Kwon HS, Lim HW, Wu J, Schnölzer M, Verdin E, et al. (2012) Three novel acetylation sites in the Foxp3 transcription factor regulate the suppressive activity of regulatory T cells. J Immunol 188: 2712-2721. doi:10.4049/jimmunol.1100903. PubMed: 22312127.
34. Gao B, Kong Q, Kemp K, Zhao YS, Fang D, (2012) Analysis of sirtuin 1 expression reveals a molecular explanation of IL-2-mediated reversal of T-cell tolerance. Proc Natl Acad Sci U S A 109: 899-904. doi:10.1073/pnas.1118462109. PubMed: 22219356.
35. Macián F, García-Cózar F, Im SH, Horton HF, Byrne MC, et al. (2002) Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109: 719-731. doi:10.1016/S0092-8674(02)00767-5. PubMed: 12086671.
36. Chow CW, Rincón M, Cavanagh J, Dickens M, Davis RJ, (1997) Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 278: 1638-1641. doi:10.1126/science.278.5343.1638. PubMed: 9374467.
37. Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, et al. (1993) The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 365: 352-355. doi:10.1038/365352a0. PubMed: 8397339.
38. Odoardi F, Sie C, Streyl K, Ulaganathan VK, Schläger C, et al. (2012) T cells become licensed in the lung to enter the central nervous system. Nature 488: 675-679. doi:10.1038/nature11337. PubMed: 22914092.
39. Choi JM, Bothwell AL, (2012) The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells 33: 217-222. doi:10.1007/s10059-012-2297-y. PubMed: 22382683.
40. Arima Y, Harada M, Kamimura D, Park JH, Kawano F, et al. (2012) Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell 148: 447-457. doi:10.1016/j.cell.2012.01.022. PubMed: 22304915.
41. Mills KH, (2011) TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 11: 807-822. PubMed: 22094985.
42. Imler TJ Jr, Petro TM, (2009) Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4- IFN-γ+ cells, and decreased macrophage IL-6 expression. Int Immunopharmacol 9: 134-143. doi:10.1016/j.intimp.2008.10.015. PubMed: 19022403.
43. Jeong MH, Yang KM, Choi YJ, Kim SD, Yoo YH, et al. (2012) Resveratrol analog, HS-1793 enhance anti-tumor immunity by reducing the CD4+CD25+ regulatory T cells in FM3A tumor bearing mice. Int Immunopharmacol 14: 328-333. doi:10.1016/j.intimp.2012.07.018. PubMed: 22884509.